SCM-198 also inhibited Aβ
-induced c-Jun N-terminal kinase (JNK) phosphorylation and IкB-к degradation in BV-2 cells. BV-2 cells were pretreated with 0.1 to 10 μM SCM, 20 μM donepezil (DON), 10 μM SP600125 (SP), 10 μM PD98059 (PD), or 20 μM SB203580 (SB) for 2 hours, followed by 30-minute Aβ1-40 stimulation. SCM could inhibit JNK activation (a, b) and IкB-к degradation (a, e), but not ERK (a, c) and p38 activation (a, d). Data represent mean ± SEM of more than three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, Tukey’s test versus only Aβ1-40-treated group; #P < 0.05, ##P < 0.01, ###P < 0.001, Tukey’s test versus control group.